Harnessing attenuation-related mutations of viral genomes: Development of a serological assay to differentiate between capripoxvirus-infected and -vaccinated animals
2023
Berguido, Francisco | Chibssa, Tesfaye Rufael | Loitsch, Angelika | Liu, Yang | Krstevski, Kiril | Djadjovski, Igor | Tuppurainen, Eeva | Petrović, Tamaš | Vidanović, Dejan | Caufour, Philippe | Settypalli, Tirumala Bharani Kumar | Grünwald-Gruber, Clemens | Grabherr, Reingard | Diallo, Adama | Cattoli, Giovanni | Lamien, Charles Euloge
Sheeppox, goatpox, and lumpy skin disease caused by the sheeppox virus (SPPV), goatpox virus (GTPV), and lumpy skin disease virus (LSDV), respectively, are diseases that affect millions of ruminants and many low-income households in endemic countries, leading to great economic losses for the ruminant industry. The three viruses are members of the Capripoxvirus genus of the Poxviridae family. Live attenuated vaccines remain the only efficient means for controlling capripox diseases. However, serological tools have not been available to differentiate infected from vaccinated animals (DIVA), though crucial for proper disease surveillance, control, and eradication efforts. We analysed the sequences of variola virus B22R homologue gene for SPPV, GTPV, and LSDV and observed significant differences between field and vaccine strains in all three capripoxvirus species, resulting in the truncation and absence of the B22R protein in major vaccines within each of the viral species. We selected and expressed a protein fragment present in wildtype viruses but absent in selected vaccine strains of all three species, taking advantage of these alterations in the B22R gene. An indirect ELISA (iELISA) developed using this protein fragment was evaluated on well-characterized sera from vaccinated, naturally and experimentally infected, and negative cattle and sheep. The developed wildtype-specific capripox DIVA iELISA showed >99% sensitivity and specificity for serum collected from animals infected with the wildtype virus. To the best of our knowledge, this is the first wildtype-specific, DIVA-capable iELISA for poxvirus diseases exploiting changes in nucleotide sequence alterations in vaccine strains.
显示更多 [+] 显示较少 [-]